UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000030359
Receipt number R000034631
Scientific Title Phase II trial of eribulin in patients with recurrent glioblastoma (ENIGMA)
Date of disclosure of the study information 2017/12/19
Last modified on 2021/10/13 15:34:13

No. Disposal Last modified on Item of update
1 Insert 2017/12/12 10:21:52
2 Update 2017/12/12 10:25:16 Last name of contact person
Last name of contact person
Division name
Division name
Date of disclosure of the study information
3 Update 2017/12/12 10:59:43 Last name of contact person
Last name of contact person
Division name
Division name
4 Update 2017/12/15 10:16:17 UMIN ID1
UMIN ID2
5 Update 2017/12/15 10:19:15 Date of disclosure of the study information
6 Update 2017/12/19 19:35:12 Name of secondary funder(s)
Name of secondary funder(s)
7 Update 2017/12/19 20:39:55 Trial characteristics_1
8 Update 2018/01/20 09:59:38 Recruitment status
9 Update 2018/06/12 09:12:42 Institutions
10 Update 2019/06/14 22:39:27 UMIN ID1
11 Update 2019/12/16 09:42:20 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
12 Update 2019/12/16 09:45:38 Date of IRB
Last follow-up date
13 Update 2020/03/16 09:24:52 UMIN ID1
14 Update 2020/04/30 14:57:05 Recruitment status
15 Update 2020/06/16 13:55:01 Institutions
16 Update 2021/10/08 13:29:39 Recruitment status
17 Update 2021/10/08 13:31:03 Number of participants that the trial has enrolled
18 Update 2021/10/08 13:47:59 Email
Organization1
Email
19 Update 2021/10/13 15:34:13 Email1
Email